KLK3 and posterior cortical atrophy: For the second option, adding enzalutamide to ADT in order to intensify the systemic treatment should be reserved for very high-risk PCa patients, as per the STAMPEDE population [13], or relapsing disease following primary treatment with high-risk features including high PSA level at relapse and short PSADT [12].